Shares of Arena Pharmaceuticals are up huge in the last week ahead of today's PDUFA date for the company's obesity drug Lorcaserin. Piper attributes a lot of the share volume to retail investors, and points out Arena is a heavily shorted name. Piper believes Lorcaserin is well positioned to penetrate the large global obesity market and sees further stock upside should the FDA approve the drug.
No comments:
Post a Comment